

Influenza Vaccine Supply and Recommendations for Prioritizing Risk Groups New York City, 2005–2006 Season

While the nation has experienced vaccine distribution delays or shortages during 3 of the last 5 influenza seasons, 4 manufacturers are providing vaccine this year (see table), and serious problems are *not* expected to occur.

Because the number of vaccine doses available at any one time may rise and fall, however, it is important to ensure that people who need flu shots **MOST** will be able to get them. Clinicians should therefore make every effort to vaccinate *first* all patients at highest risk for complications from the flu:

- All people age 65 and older
- All residents of nursing homes and other long-term-care facilities
- All children age 6 to 23 months
- All people age 6 months and older with chronic medical conditions*
- All pregnant women
- All out-of-home caregivers and household contacts of children under 6 months
- All healthcare personnel with direct patient contact

*Diabetes, heart, kidney or lung disease, HIV/AIDS, and diseases that affect the immune system.

Once these high-risk patients have been vaccinated, all patients should be offered influenza vaccination. For more information and updates throughout the season, visit: www.nyc.gov/health/flu

Influenza vaccine manufacturers and projected supplies for the 2005-06 influenza season					
Manufacturer	Vaccine	Formulation	Contains thimerosal preservation	Age Indication	No. of projected doses
Sanofi Pasteur, Inc	Fluzone® trivalent inactivated influenza vaccine (TIV)	Multidose vial Single-dose prefilled 0.5 mL syringe or vial Single-dose prefilled 0.25 mL syringe	Yes No No	≥6 mos ≥36 mos 6-35 mos	60 million*
Chiron Corporation	Fluvirin™ TIV	Multidose vial Single-dose prefilled 0.05 mL syringe	Yes No§	≥4 yrs ≥4 yrs	18–26 million†
GlaxoSmithKline, Inc	Fluarix™ TIV	Single-dose prefilled 0.5 mL syringe	No§	≥18 yrs	18 million
Medimmune Vaccines, Inc	FluMist™ live, attenuated Influenza vaccine (LAIV)	Single-dose nasal sprayer	No	Healthy, nonpregnant person aged 5–49 yrs	3 million

* Approximately 6–8 million of the 60 million doses are projected to be distributed in single-dose prefilled syringes or vials.

† Chiron projects that the majority of its vaccine doses will be distributed by the end of October 2005; the exact timing of distribution was uncertain as of August 30, 2005. A minimal number of doses of Chiron thimerosal-free formulation might be available in late season.

§ These preparations contain traces of thimerosal from the production process.

Adapted from Morbidity and Mortality Weekly Report, Centers for Disease Control and Prevention, September 2, 2005/154(34);850